Partners HealthCare

Biobank Disease Challenge

Welcome to the Partners HealthCare Biobank Disease Challenge

Partners HealthCare is hosting a "Biobank Disease Challenge," an articial intelligence and machine learning data analytics competition and it is open to researchers across the United States.

The goal of this competition is to enable major translational data science players to leverage the Partners HealthCare Biobank in order to develop better phenotypic algorithms for clinical and basic research.

Registration will be open on April 23 and close on July 13, 2018 to 50 teams. Prizes will be awarded for the best machine learning models and visualizations.

Tentative Challenge Schedule

  • April 23, 2018 // Registration Opens
  • July 13, 2018 5 PM EST// CLOSED

  • Opening Soon // Practice on Platform
  • September 12 – October 10, 2018 // Competition

The following prize awards are as follows:

  • First place: $15,000
  • Second place: $10,000
  • Third place: $5,000

Partners Biobank Disease Challenge Description


The Partners HealthCare Biobank is an enterprise-wide initiative whose goal is to provide a foundation for the next generation of translational research studies of genotype, environment, gene-environment interaction, biomarker and family history associations with disease phenotypes (Karlson, 2016). The Biobank has leveraged in-person and electronic recruitment methods to enroll over 80,000 participants since 2010. All participants in the Biobank have their electronic health record (EHR) data linked to biospecimens, genotype data and self-reported health survey information (Gainer, 2016). The data is aggregated into an i2b2 environment called the Biobank Portal to facilitate querying and analysis in a web user interface and data backend (Murphy, 2010).

EHR data is available for large populations, can be quickly ascertained for research and provides a naturalistic data collection pattern. These benefits come with significant limitations, however. Namely, the data has significant data quality and completeness biases that can be difficult to use to derive new knowledge or identify interesting signals. One of the earliest use cases of leveraging this EHR data is for building computed phenotype algorithms to use for GWAS and other genomic data analyses (Kohane, 2011; Bowton, 2014; Castro, 2016). Computed phenotypes are machine learning algorithms to identify a patient’s true disease state from raw EHR data. Once true disease status is known, additional models can be derived to predict future onset of disease, quantify severity of disease and/or identify sub-populations within diseases.

The Challenge

The Biobank Disease Challenge is a two-part challenge:

Part 1: Develop Computed Phenotypes for 5 Diseases

In this challenge we are asking participants to develop computed phenotype machine learning algorithms to identify 5 disease states (to be released at the beginning of the challenge) of all patients enrolled in the Partners Biobank. Algorithms must be developed against available EHR data and limited training data. These algorithms will be assessed against gold standard labels from clinician assessment of a patient’s full clinical chart. All submissions should include an algorithm score for each patient and disease state. Scores will be ranked for each disease and an area under the ROC curve (AUC) will be calculated based on the validation dataset. The final score will be partially based on the average of the 5 disease AUCs.

Part 2: AI for Novel Insights from EHR data

The second part is an open-ended task that will invite teams to develop artificial intelligence algorithms to identify interesting patterns within one of the disease populations in part 1 of the challenge. In this challenge, users can choose any analysis/model that provides insight from the EHR data. Examples might include (but not limited to):

  • Group patients into clinically meaningful clusters
  • Stratify patients by disease severity
  • Identify longitudinal patterns of disease or care
  • Identify predictors of treatment initiation and response
The evaluation of this part of the challenge is subjective and will be judged based on innovation and clinical insightfulness.

All submissions must include a fully self-contained R or Jupyter Notebook in HTML format, built towards human-interpretability with explanatory visualizations.

Judging Panel

A panel of judges with expertise in medicine, machine learning and health informatics has been assembled to judge each submission. The final judging score to determine the winners of the challenge will be compiled as below.

Judging Criteria

Part 1: Algorithm Performance

Average AUC: ______ (1-20)

Interpretability of the models: _____ (1-10)

Part 2: Innovation/Insight

Design of Methods / Analysis ____ (1-5)

Innovation ____ (1-5)

Clinical Importance ____ (1-10)

Clarity of Results / Visualizations ____ (1-10)


Doshi-Velez, F., Ge, Y. and Kohane, I., 2014. Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis. Pediatrics, 133(1), pp.e54-e63.

Murphy, S.N., Weber, G., Mendis, M., Gainer, V., Chueh, H.C., Churchill, S. and Kohane, I., 2010. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2). Journal of the American Medical Informatics Association, 17(2), pp.124-130.

McCoy Jr, T.H., Castro, V.M., Hart, K.L., Pellegrini, A.M., Yu, S., Cai, T. and Perlis, R.H., 2018. Genome-wide association study of dimensional psychopathology using electronic health records. Biological psychiatry.

Karlson, E.W., Boutin, N.T., Hoffnagle, A.G. and Allen, N.L., 2016. Building the partners healthcare biobank at partners personalized medicine: informed consent, return of research results, recruitment lessons and operational considerations. Journal of personalized medicine, 6(1), p.2.

Gainer, V.S., Cagan, A., Castro, V.M., Duey, S., Ghosh, B., Goodson, A.P., Goryachev, S., Metta, R., Wang, T.D., Wattanasin, N. and Murphy, S.N., 2016. The Biobank Portal for Partners personalized medicine: a query tool for working with consented biobank samples, genotypes, and phenotypes using i2b2. Journal of personalized medicine, 6(1), p.11.

Kohane, I.S., 2011. Using electronic health records to drive discovery in disease genomics. Nature Reviews Genetics, 12(6), p.417.

Bowton, E., Field, J.R., Wang, S., Schildcrout, J.S., Van Driest, S.L., Delaney, J.T., Cowan, J., Weeke, P., Mosley, J.D., Wells, Q.S. and Karnes, J.H., 2014. Biobanks and electronic medical records: enabling cost-effective research. Science translational medicine, 6(234), pp.234cm3-234cm3.

Castro, V.M., Minnier, J., Murphy, S.N., Kohane, I., Churchill, S.E., Gainer, V., Cai, T., Hoffnagle, A.G., Dai, Y., Block, S. and Weill, S.R., 2015. Validation of electronic health record phenotyping of bipolar disorder cases and controls. American Journal of Psychiatry, 172(4), pp.363-372.

Already Registered? Sign In